Effect of switching from tiotropium to glycopyrronium on pulmonary function in patients with COPD.

Effect of switching from tiotropium to glycopyrronium on pulmonary function in patients with COPD. - Effect of switching from tiotropium to glycopyrronium on pulmonary function in patients with COPD.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015244

Enrollment

Registered

2014-09-24

Start date

2014-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease(COPD)

Interventions

Switching from tiotropium to glycopirronium

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)patients who are diagnosed with GOLD stage 1-4 COPD 2)current or former smokers having at least 10pack-years smoking history 3)patients who have been treated with tiotropium for more than 16weeks before enrollment 4)obtained written informed consent

Exclusion criteria

Exclusion criteria: 1)patients who need systemic corcicosteroidal administration and/or hospitalization for COPD exacerbation within 16 weeks prior to enrollment 2)patients having lower respiratory infection within 16weeks prior to enrollment 3)patients with home oxygen therapy 4)patients with bronchial asthma or chronic respiratory disease such as bronchiectasis,pulmonary fibrosis and pneumoconiosis 5)patients with uncontrolled severe complications 6)patients who seem inadequate for this study by investigators

Design outcomes

Primary

Measure	Time frame
FEV1.0 respiratory resistance index(R5,R20,R5-20,X5,Fres)	—

Secondary

Measure	Time frame
CAT score	—

Countries

Japan

Contacts

Public ContactHirohisa Ichikawa

KKR Takamatsu hospital Respiratory tract medicine

irb@kkr-ta-hp.gr.jp087-861-3261

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026